Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
暂无分享,去创建一个
[1] O. Levran,et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction , 2013, Addiction biology.
[2] J. Brockmöller,et al. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.
[3] Su-Jun Lee,et al. Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine , 2013, Front. Gene..
[4] D. Rozman,et al. Molecular Interactions between NAFLD and Xenobiotic Metabolism , 2013, Front. Gene..
[5] H. Brauch,et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M Schwab,et al. Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver , 2011, The Pharmacogenomics Journal.
[7] J. Stockman. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis , 2013 .
[8] Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity , 2013, European Journal of Drug Metabolism and Pharmacokinetics.
[9] Marylyn D Ritchie,et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants , 2012, Pharmacogenetics and genomics.
[10] M. Turpeinen,et al. Cytochrome P450 2B6: function, genetics, and clinical relevance , 2012, Drug metabolism and drug interactions.
[11] W. Haefeli,et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study , 2011, The Pharmacogenomics Journal.
[12] Lang Li,et al. Impact of the Interaction between 3′-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes , 2012, Front. Gene..
[13] Juxiang Yuan,et al. CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies , 2012, BMC Cancer.
[14] Tai-ping He,et al. Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis , 2012, Molecular Biology Reports.
[15] N. Helsby,et al. Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19 , 2012, Front. Gene..
[16] W. Sadee. The Relevance of “Missing Heritability ” in Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.
[17] Yusuke Nakamura,et al. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.
[18] V. Stanton. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.
[19] C. Caldas,et al. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.
[20] D. Kim,et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. , 2012, The American journal of cardiology.
[21] G. Koren,et al. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. , 2012, Current drug metabolism.
[22] F. Innocenti,et al. Liver expression quantitative trait loci: a foundation for pharmacogenomic research , 2012, Front. Gene..
[23] M. Niemi,et al. PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo , 2012, Clinical pharmacology and therapeutics.
[24] H. Raunio,et al. CYP2A6: genetics, structure, regulation, and function , 2012, Drug metabolism and drug interactions.
[25] A. Wikman,et al. Metabolism of bilirubin by human cytochrome P450 2A6. , 2012, Toxicology and applied pharmacology.
[26] Andrew A Somogyi,et al. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. , 2012, British journal of clinical pharmacology.
[27] A. Henney,et al. The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[28] H. Baelde,et al. CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele , 2012, Drug Metabolism and Disposition.
[29] M. Stoneking,et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. , 2012, Pharmacogenomics.
[30] J. Cuzick,et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.
[31] P. Neven,et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.
[32] U. Zanger,et al. Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. , 2012, Toxicology.
[33] J E Lunshof,et al. Pharmacogenomic Testing: Knowing More, Doing Better , 2012, Clinical pharmacology and therapeutics.
[34] H. Brauch,et al. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. , 2012, Human molecular genetics.
[35] N. Helsby,et al. Which CYP2B6 Variants Have Functional Consequences for Cyclophosphamide Bioactivation? , 2012, Drug Metabolism and Disposition.
[36] D. Mansuy,et al. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. , 2012, Chemical research in toxicology.
[37] Joseph K. Pickrell,et al. A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.
[38] Z. Dong,et al. Association of the CYP1B1 Leu432Val polymorphism with the risk of prostate cancer: a meta-analysis , 2012, Molecular Biology Reports.
[39] J. Cornuz,et al. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking , 2012, Pharmacogenetics and genomics.
[40] K. Makar,et al. Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo , 2012, Drug Metabolism and Disposition.
[41] Tetsuya Terasaki,et al. Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.
[42] Marylyn D. Ritchie,et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients , 2012, Pharmacogenetics and genomics.
[43] N. Djebli,et al. Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite , 2012, Drug Metabolism and Disposition.
[44] Greyson Twist,et al. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. , 2012, Pharmacogenomics.
[45] T. Lesnick,et al. Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. , 2012, Leukemia research.
[46] Ulrich M. Zanger,et al. Metabolism of drugs and other xenobiotics , 2012 .
[47] K. Jain. Applications of AmpliChip™ CYP450 , 2012, Molecular Diagnosis.
[48] Yusuke Nakamura,et al. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans , 2011, European Journal of Clinical Pharmacology.
[49] Michael V Holmes,et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. , 2011, JAMA.
[50] J. Halpert,et al. The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. , 2011, Biochemistry.
[51] A. Hofman,et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study , 2011, Pharmacogenetics and genomics.
[52] R. Tyndale,et al. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.
[53] J. Halpert,et al. Structures of Cytochrome P450 2B6 Bound to 4-Benzylpyridine and 4-(4-Nitrobenzyl)pyridine: Insight into Inhibitor Binding and Rearrangement of Active Site Side Chains , 2011, Molecular Pharmacology.
[54] Jing Yuan,et al. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine , 2011, Pharmacogenetics and genomics.
[55] B. Fromenty,et al. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity , 2011, The FEBS journal.
[56] Takuya Kumamoto,et al. Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262 , 2011, Drug Metabolism and Disposition.
[57] Lang Li,et al. Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age , 2011, Clinical pharmacology and therapeutics.
[58] V. Haufroid,et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.
[59] V. Haufroid,et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.
[60] M. Hiratsuka,et al. Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether , 2011, Drug Metabolism and Disposition.
[61] B. Fromenty,et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.
[62] D. Billheimer,et al. Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease , 2011, Drug Metabolism and Disposition.
[63] C. Thangavel,et al. Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men. , 2011, Endocrinology.
[64] Warfarin pharmacogenetics meets clinical use , 2011, Blood.
[65] Paul Flicek,et al. The functional spectrum of low-frequency coding variation , 2011, Genome Biology.
[66] M. Spitz,et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. , 2011, Journal of the National Cancer Institute.
[67] F. Guengerich,et al. Orphans in the Human Cytochrome P450 Superfamily: Approaches to Discovering Functions and Relevance in Pharmacology , 2011, Pharmacological Reviews.
[68] K. Verbeke,et al. In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine‐Treated as Compared With Tacrolimus‐Treated Renal Allograft Recipients , 2011, Clinical pharmacology and therapeutics.
[69] T. Harrer,et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. , 2011, The Journal of antimicrobial chemotherapy.
[70] Andreas Zell,et al. Inferring statin-induced gene regulatory relationships in primary human hepatocytes , 2011, Bioinform..
[71] R. Zemni,et al. Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population , 2011, Journal of Genetics.
[72] J. Ibrahim,et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] V. Manolopoulos,et al. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. , 2011, Pharmacogenomics.
[74] D. Waxman,et al. Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease , 2011, PloS one.
[75] W. Sadee,et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.
[76] H. Inoko,et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients , 2011, Bone Marrow Transplantation.
[77] Xin A. Zhang,et al. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. , 2011, Advanced drug delivery reviews.
[78] U. Zanger,et al. MIRNA-DISTILLER: A Stand-Alone Application to Compile microRNA Data from Databases , 2011, Front. Gene..
[79] M. Ingelman-Sundberg,et al. The Ligands of Estrogen Receptor α Regulate Cytochrome P4502C9 (CYP2C9) Expression , 2011, Journal of Pharmacology and Experimental Therapeutics.
[80] J. Cornuz,et al. Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility , 2011, Clinical pharmacology and therapeutics.
[81] A. Figueiras,et al. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review , 2011, Pharmacogenetics and genomics.
[82] R. Brugada,et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel , 2011, Heart.
[83] Gerd Mikus,et al. Pharmacogenomics of the triazole antifungal agent voriconazole. , 2011, Pharmacogenomics.
[84] D. Podzamczer,et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent , 2011, AIDS.
[85] B. Giusti,et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis , 2011, The Pharmacogenomics Journal.
[86] R. Mägi,et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. , 2011, Human molecular genetics.
[87] T. Fehm,et al. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.
[88] L. Natarajan,et al. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.
[89] Russ B Altman,et al. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. , 2011, Pharmacogenetics and genomics.
[90] M. Hellmich,et al. Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide , 2011, Drug Metabolism and Disposition.
[91] Christopher D. Brown,et al. Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue , 2011, PLoS genetics.
[92] W. Leppert. CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain , 2011, Pharmacology.
[93] K. Giacomini,et al. Consequences of POR mutations and polymorphisms , 2011, Molecular and Cellular Endocrinology.
[94] W. Vach,et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer , 2011, The Pharmacogenomics Journal.
[95] R. Milne,et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.
[96] Eun-Young Kim,et al. Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo , 2011, Drug Metabolism and Disposition.
[97] D. Kiel,et al. Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms , 2011, PLoS genetics.
[98] E. Rimm,et al. Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption , 2011, PLoS genetics.
[99] W. Miller,et al. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. , 2011, Molecular endocrinology.
[100] Andrew D. Johnson,et al. Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy , 2011, Clinical pharmacology and therapeutics.
[101] Wolfgang Weiss,et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..
[102] C. Adithan,et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients , 2011, European Journal of Clinical Pharmacology.
[103] W. Vach,et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.
[104] Min Huang,et al. MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation. , 2011, Molecular endocrinology.
[105] Vladimir B. Bajic,et al. dPORE-miRNA: Polymorphic Regulation of MicroRNA Genes , 2011, PloS one.
[106] L. Bertilsson,et al. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.
[107] H. Bartsch,et al. Ethanol‐mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA‐lesions , 2011, International journal of cancer.
[108] Nancy J. Cox,et al. A Study of CNVs As Trait-Associated Polymorphisms and As Expression Quantitative Trait Loci , 2011, PLoS genetics.
[109] S-M He,et al. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. , 2011, Current medicinal chemistry.
[110] Matthias Cavassini,et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. , 2011, The Journal of infectious diseases.
[111] D. Pounder,et al. CYP2B6 and OPRM1 gene variations predict methadone‐related deaths , 2011, Addiction biology.
[112] A. Hofman,et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes , 2011, Pharmacogenetics and genomics.
[113] A. Serretti,et al. Pharmacogenetics of Antidepressants , 2010, Front. Pharmacol..
[114] Shengying Qin,et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. , 2008, Genomics.
[115] C. Flück,et al. Clinical and biochemical consequences of p450 oxidoreductase deficiency. , 2011, Endocrine development.
[116] Michal Otyepka,et al. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. , 2011, Biochimica et biophysica acta.
[117] Tetsuya Terasaki,et al. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. , 2011, Journal of pharmaceutical sciences.
[118] C. Buechler,et al. Does hepatic steatosis affect drug metabolizing enzymes in the liver? , 2011, Current drug metabolism.
[119] Yusuke Nakamura,et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients , 2011, Breast Cancer Research and Treatment.
[120] G. Hortobagyi,et al. Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.
[121] J. Turgeon,et al. Metabolic Activity and mRNA Levels of Human Cardiac CYP450s Involved in Drug Metabolism , 2010, PloS one.
[122] J. Ritz,et al. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation , 2010, American journal of hematology.
[123] U. Fuhr,et al. University of Birmingham Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency , 2010 .
[124] Stephen T. C. Wong,et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. , 2010, Pharmacogenomics.
[125] K. Giacomini,et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro , 2010, Pharmacogenetics and genomics.
[126] M. Ingelman-Sundberg,et al. Regulation of CYP2C19 Expression by Estrogen Receptor α: Implications for Estrogen-Dependent Inhibition of Drug Metabolism , 2010, Molecular Pharmacology.
[127] Mark George Thomas,et al. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme , 2010, Pharmacogenetics and genomics.
[128] Hongbing Wang,et al. Synergistically Enhanced CYP2B6 Inducibility between a Polymorphic Mutation in CYP2B6 Promoter and Pregnane X Receptor Activation , 2010, Molecular Pharmacology.
[129] Robert T. Taylor,et al. Role of Epigenetic Mechanisms in Differential Regulation of the Dioxin-Inducible Human CYP1A1 and CYP1B1 Genes , 2010, Molecular Pharmacology.
[130] M. Schwab,et al. Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver , 2010, Front. Pharmacol..
[131] Ute Hofmann,et al. Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes , 2010, Drug Metabolism and Disposition.
[132] D. Clifford,et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. , 2010, The Journal of infectious diseases.
[133] Victoria M. Pratt,et al. Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants , 2010, Front. Pharmacol..
[134] C. Caldas,et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen , 2010, Breast Cancer Research.
[135] Xia Yang,et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. , 2010, Genome research.
[136] Duan Liu,et al. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[137] G. Hankins,et al. Bupropion metabolism by human placenta. , 2010, Biochemical pharmacology.
[138] C. Cellier,et al. CYP2C9*3 Loss‐of‐Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin , 2010, Clinical pharmacology and therapeutics.
[139] M. Gawaz,et al. Platelet pharmacogenomics , 2010, Journal of thrombosis and haemostasis : JTH.
[140] L. Wienkers,et al. Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.
[141] F. Stüber,et al. Personalized therapy in pain management: where do we stand? , 2010, Pharmacogenomics.
[142] M. Hiratsuka,et al. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2–CYP2B6.28, except CYP2B6.22) , 2010, Pharmacogenetics and genomics.
[143] C. Gieger,et al. Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.
[144] M. Ingelman-Sundberg,et al. The past, present and future of pharmacoepigenomics. , 2010, Pharmacogenomics.
[145] Bo Wang,et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.
[146] S. Janković,et al. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism , 2010, European Journal of Clinical Pharmacology.
[147] Yasuhiro Aoki,et al. Human CYP2E1 is regulated by miR-378. , 2010, Biochemical pharmacology.
[148] C. Staatz,et al. Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.
[149] Stephanie C Huelga,et al. Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å Resolution , 2010, Molecular Pharmacology.
[150] B. Wouters,et al. Diminished Carcinogen Detoxification Is a Novel Mechanism for Hypoxia-inducible Factor 1-mediated Genetic Instability* , 2010, The Journal of Biological Chemistry.
[151] Yusuke Nakamura,et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[152] Y. Hofmann,et al. New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4 , 2010, Drug Metabolism and Disposition.
[153] S. Taudien,et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability , 2010, Pharmacogenetics and genomics.
[154] S. Strom,et al. Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression , 2010, Journal of Pharmacology and Experimental Therapeutics.
[155] J. Lafitte,et al. Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. , 2010, Biochimie.
[156] P. Farndon,et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. , 2010, British journal of clinical pharmacology.
[157] Haiyan Yang,et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. , 2010, European journal of cancer.
[158] M. Rieder,et al. Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects , 2010, Drug Metabolism and Disposition.
[159] D Jamieson,et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide , 2010, British Journal of Cancer.
[160] D. Trafalis,et al. CYP2E1 and risk of chemically mediated cancers , 2010, Expert opinion on drug metabolism & toxicology.
[161] B. Brüne,et al. MicroRNA-27b Contributes to Lipopolysaccharide-mediated Peroxisome Proliferator-activated Receptor γ (PPARγ) mRNA Destabilization* , 2010, The Journal of Biological Chemistry.
[162] N. Benowitz,et al. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. , 2010, Pharmacogenomics.
[163] N. Vermeulen,et al. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression , 2010, The Pharmacogenomics Journal.
[164] A. Kastrati,et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.
[165] Matthias Cavassini,et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir , 2010, Pharmacogenetics and genomics.
[166] S. Leucht,et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome , 2010, The Pharmacogenomics Journal.
[167] B. Masters,et al. Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of Defect , 2010, Drug Metabolism and Disposition.
[168] Caroline A. Lee,et al. Identification of Novel Substrates for Human Cytochrome P450 2J2 , 2010, Drug Metabolism and Disposition.
[169] K. Yoshinari,et al. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. , 2010, Biochemical pharmacology.
[170] Jyh-Chin Yang,et al. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection , 2010, Expert opinion on drug metabolism & toxicology.
[171] J. N. van den Anker,et al. Efavirenz in the therapy of HIV infection , 2010, Expert opinion on drug metabolism & toxicology.
[172] M. Perera. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? , 2010, Expert opinion on drug metabolism & toxicology.
[173] R. Chakraborty,et al. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations , 2010, Human mutation.
[174] Osamu Okazaki,et al. Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.
[175] F. Baumann,et al. Gender difference in ifosfamide metabolism by human liver microsomes , 2001, European Journal of Drug Metabolism and Pharmacokinetics.
[176] J. Dungan,et al. Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen , 2010 .
[177] C. Staatz,et al. Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.
[178] C. Gieger,et al. Sequence variants at CHRNB 3 – CHRNA 6 and CYP 2 A 6 affect smoking behavior , 2010 .
[179] T. Sergentanis,et al. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.
[180] R. Tyndale,et al. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors , 2010, European Journal of Clinical Pharmacology.
[181] T. Sergentanis,et al. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.
[182] Lei Yao,et al. Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects , 2010, Breast Cancer Research and Treatment.
[183] Shingo Takagi,et al. MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle* , 2009, The Journal of Biological Chemistry.
[184] C. Dani,et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. , 2009, Biochemical and biophysical research communications.
[185] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[186] P. Kremsner,et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. , 2009, The Lancet. Infectious diseases.
[187] U. Fuhr,et al. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. , 2009, Basic & clinical pharmacology & toxicology.
[188] S. Willmann,et al. Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.
[189] M. Bochud,et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test , 2009, Pharmacogenetics and genomics.
[190] Shu-Feng Zhou,et al. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. , 2009, Current drug metabolism.
[191] T. Kamataki,et al. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[192] T. Warner,et al. The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα In Vitro and In Vivo , 2009, PloS one.
[193] Dale Hattis,et al. Genetic Polymorphism in CYP2E1: Population Distribution of CYP2E1 Activity , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.
[194] S. Bojesen,et al. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals , 2009, The Pharmacogenomics Journal.
[195] M. Pirmohamed. The applications of pharmacogenetics to prescribing: what is currently practicable? , 2009, Clinical medicine.
[196] Yuzhuo Pan,et al. MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.
[197] Fernando Rivadeneira,et al. A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.
[198] Wei Zhang,et al. A pharmacogene database enhanced by the 1000 Genomes Project. , 2009, Pharmacogenetics and genomics.
[199] H. Brauch,et al. Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.
[200] C. Aquilante,et al. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. , 2009, Pharmacogenomics.
[201] S. Bojesen,et al. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50 000 individuals , 2009, Pharmacogenetics and genomics.
[202] Shu-Feng Zhou,et al. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. , 2009, Current drug metabolism.
[203] M. T. Donato,et al. Cytochrome p450 and steatosis. , 2009, Current drug metabolism.
[204] Michael Müller,et al. Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.
[205] J. Halperin,et al. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.
[206] Dennis Shasha,et al. miRò: a miRNA knowledge base , 2009, Database J. Biol. Databases Curation.
[207] Paolo Palatini,et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension , 2009, Journal of hypertension.
[208] C. Eap,et al. ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine , 2009, Journal of clinical psychopharmacology.
[209] H. Bartsch,et al. Ethanol‐induced cytochrome P4502E1 causes carcinogenic etheno‐DNA lesions in alcoholic liver disease , 2009, Hepatology.
[210] D. Waxman,et al. Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes , 2009, Molecular Pharmacology.
[211] J. Stevens,et al. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. , 2009, Biochemical pharmacology.
[212] Daniel E Jonas,et al. Genetic and clinical factors relating to warfarin dosing. , 2009, Trends in pharmacological sciences.
[213] M. Ingelman-Sundberg,et al. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. , 2009, Pharmacogenetics and genomics.
[214] M. Ingelman-Sundberg,et al. Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone , 2009, Drug Metabolism and Disposition.
[215] M. Loriot,et al. Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function , 2009, Drug Metabolism and Disposition.
[216] J. Goldstein,et al. The transcriptional regulation of the human CYP2C genes. , 2009, Current drug metabolism.
[217] A. McLachlan,et al. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. , 2009, Current drug metabolism.
[218] Ding Ma,et al. Selective Inhibitors of CYP2J2 Related to Terfenadine Exhibit Strong Activity against Human Cancers in Vitro and in Vivo , 2009, Journal of Pharmacology and Experimental Therapeutics.
[219] L. Milani,et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers , 2009, The Pharmacogenomics Journal.
[220] M. Moya,et al. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. , 2009, Current drug metabolism.
[221] K. Jamil,et al. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. , 2009, Urology journal.
[222] U. Hofmann,et al. A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes , 2009, Drug Metabolism and Disposition.
[223] M. Youle,et al. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population , 2009, HIV medicine.
[224] Katrin Marcus,et al. Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver , 2009, Proteomics.
[225] J. Dressman,et al. Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.
[226] A. Telenti,et al. Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.
[227] M. Schwab,et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. , 2009, Pharmacogenomics.
[228] Jingbo Wang,et al. Predicting potentially functional SNPs in drug-response genes. , 2009, Pharmacogenomics.
[229] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[230] Huldrych F. Günthard,et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.
[231] V. Haufroid,et al. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.
[232] T. Eschenhagen,et al. Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study , 2009, Clinical pharmacology and therapeutics.
[233] G. Di Fede,et al. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. , 2009, Bone.
[234] R. Porcher,et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia , 2009, Leukemia.
[235] J. Halpert,et al. Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs , 2009, Drug Metabolism and Disposition.
[236] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[237] S. Hercberg,et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. , 2009, The Lancet. Oncology.
[238] M. Ratain,et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans , 2009, The Pharmacogenomics Journal.
[239] D. Hochstrasser,et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.
[240] S. Oka,et al. Successful genotype-tailored treatment with small-dose efavirenz. , 2009, AIDS.
[241] G. Montalescot,et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.
[242] F. Chiafari,et al. DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping , 2009, CNS Spectrums.
[243] A. Hofman,et al. Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β‐Blocker Users , 2009, Clinical pharmacology and therapeutics.
[244] B. Carleton,et al. Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.
[245] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[246] Tongbin Li,et al. miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..
[247] R. Tyndale,et al. Molecular genetics of nicotine metabolism. , 2009, Handbook of experimental pharmacology.
[248] M. Ingelman-Sundberg,et al. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment , 2009, Human Genetics.
[249] M. Ingelman-Sundberg,et al. CNVs of human genes and their implication in pharmacogenetics , 2009, Cytogenetic and Genome Research.
[250] D. Nebert,et al. Endogenous Functions of the Aryl Hydrocarbon Receptor (AHR): Intersection of Cytochrome P450 1 (CYP1)-metabolized Eicosanoids and AHR Biology* , 2008, Journal of Biological Chemistry.
[251] Masahiro Hiratsuka,et al. Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.
[252] R. Albano,et al. CYP2A6 polymorphisms and risk for tobacco-related cancers. , 2008, Pharmacogenomics.
[253] K. Yoshinari,et al. Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo , 2008, Drug Metabolism and Disposition.
[254] K. Kidd,et al. Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene , 2008, The Pharmacogenomics Journal.
[255] Namandjé N. Bumpus,et al. Investigation of the Mechanisms Underlying the Differential Effects of the K262R Mutation of P450 2B6 on Catalytic Activity , 2008, Molecular Pharmacology.
[256] J. Aberg,et al. Clinical impact of patient population differences and genomic variation in efavirenz therapy , 2008, AIDS.
[257] M. Gawaz,et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. , 2008, Pharmacogenomics.
[258] M. Ingelman-Sundberg,et al. Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme , 2008, Human mutation.
[259] M. Schwab,et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.
[260] S. Marsh,et al. Developmental Changes in Human Liver CYP2D6 Expression , 2008, Drug Metabolism and Disposition.
[261] J. Schenkman,et al. Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma , 2008, Pharmacogenetics and genomics.
[262] Eun-Young Kim,et al. Genetic polymorphism of hepatocyte nuclear factor‐4α influences human cytochrome P450 2D6 activity , 2008, Hepatology.
[263] M. Ingelman-Sundberg,et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism , 2008, The Pharmacogenomics Journal.
[264] M. Ingelman-Sundberg,et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects , 2008, European Journal of Clinical Pharmacology.
[265] B. Masters,et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. , 2008, Archives of biochemistry and biophysics.
[266] K. Yoshinari,et al. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. , 2008, Biochemical pharmacology.
[267] U. Hofmann,et al. Propafenone for the Prevention of Atrial Tachyarrhythmias After Cardiac Surgery: A Randomized, Double‐blind Placebo‐controlled Trial , 2008, Clinical pharmacology and therapeutics.
[268] J. Nieman,et al. Bioactivation of Flutamide Metabolites by Human Liver Microsomes , 2008, Drug Metabolism and Disposition.
[269] U. Zanger. Chapter 8:The CYP2D Subfamily , 2008 .
[270] Sang Chung,et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process , 2008, Journal of clinical pharmacology.
[271] M. Rieder,et al. Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression , 2008, Molecular Pharmacology.
[272] H. Yamazaki,et al. Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.
[273] R. Asinger,et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[274] A. Gunes,et al. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. , 2008, Pharmacogenomics.
[275] Kazuhiro Araki,et al. CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1 , 2008, Cancer science.
[276] M. Ingelman-Sundberg,et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.
[277] John D. Storey,et al. Mapping the Genetic Architecture of Gene Expression in Human Liver , 2008, PLoS biology.
[278] Shingo Takagi,et al. Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4* , 2008, Journal of Biological Chemistry.
[279] M. Schwab,et al. Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver , 2008, Journal of Pharmacology and Experimental Therapeutics.
[280] Marie-Anne Loriot,et al. Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. , 2008, Biochimie.
[281] A. Cederbaum,et al. CYP2E1 and oxidative liver injury by alcohol. , 2008, Free radical biology & medicine.
[282] Kathleen M. Giacomini,et al. Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations , 2008, Proceedings of the National Academy of Sciences.
[283] Zhongqiu Wang,et al. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. , 2008, Lung cancer.
[284] Z. Dvořák,et al. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. , 2008, Current drug metabolism.
[285] V. Vasiliou,et al. Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.
[286] A. Telenti,et al. Pharmacogenetics of anti-HIV drugs. , 2008, Annual review of pharmacology and toxicology.
[287] J. Pascussi,et al. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. , 2008, Annual review of pharmacology and toxicology.
[288] Steven N Hart,et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism , 2008, Pharmacogenetics and genomics.
[289] P. Neuvonen,et al. Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone , 2008, Drug Metabolism and Disposition.
[290] S. Strom,et al. Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression , 2008, Drug Metabolism and Disposition.
[291] J. Pascussi,et al. Dexamethasone-Mediated Up-Regulation of Human CYP2A6 Involves the Glucocorticoid Receptor and Increased Binding of Hepatic Nuclear Factor 4α to the Proximal Promoter , 2007, Molecular Pharmacology.
[292] W. Tan,et al. Expression of cytochrome P4502E1 in human liver: Relationship between genotype and phenotype in Chinese , 2001, Science in China Series C: Life Sciences.
[293] U. Zanger,et al. Polymorphic Cytochromes P450 CYP2B6 and CYP2D6 : Recent Advances on Single Nucleotide Polymorphisms Affecting Splicing , 2008 .
[294] A. Rostami-Hodjegan,et al. CYP2D6 is primarily responsible for the metabolism of clomiphene. , 2008, Drug metabolism and pharmacokinetics.
[295] B. Ring,et al. In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine , 2008, Clinical pharmacokinetics.
[296] Stefan Willmann,et al. Physiology-Based Simulations of a Pathological Condition , 2008, Clinical pharmacokinetics.
[297] E. Hodgson,et al. Enzyme Induction and Cytotoxicity in Human Hepatocytes by Chlorpyrifos and N,N-Diethyl-m-toluamide (DEET) , 2008, Drug metabolism and drug interactions.
[298] Fu-jun Liu,et al. The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. , 2008, The Biochemical journal.
[299] F. Guengerich. Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.
[300] Prosper Chonzi,et al. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.
[301] D. Banerjee,et al. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. , 2007, Pharmacogenomics.
[302] Wolfgang Simon,et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[303] S. Strom,et al. Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. , 2007, Biochemical pharmacology.
[304] R. Tyndale,et al. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. , 2007, Pharmacogenomics.
[305] S. Matsushita,et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[306] L. Bertilsson. Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects , 2007, Clinical pharmacology and therapeutics.
[307] Lang Li,et al. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.
[308] S. Kyo,et al. Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor , 2007, Drug Metabolism and Disposition.
[309] A. El-Sohemy,et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. , 2006, JAMA.
[310] M. Eichelbaum,et al. Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole , 2007, Clinical pharmacology and therapeutics.
[311] P. Beaune,et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues , 2007, Pharmacogenetics and genomics.
[312] P. Zimmerman,et al. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. , 2007, British journal of clinical pharmacology.
[313] J. Hakkola,et al. Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells , 2007, Molecular Pharmacology.
[314] Edward T. Morgan,et al. Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.
[315] D. Mansuy,et al. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. , 2007, Archives of biochemistry and biophysics.
[316] D. Banerjee,et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance , 2007, Proceedings of the National Academy of Sciences.
[317] D. Moore,et al. Alterations in xenobiotic metabolism in the long‐lived Little mice , 2007, Aging cell.
[318] P. Rosenthal,et al. Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa , 2007, Clinical pharmacology and therapeutics.
[319] D. Seripa,et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. , 2007, Gastroenterology.
[320] P. Beaune,et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. , 2007, Pharmacogenomics.
[321] M. Schwab,et al. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.
[322] J. Schwartz. The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology , 2007, Clinical pharmacology and therapeutics.
[323] R. Finn,et al. Conditional Deletion of Cytochrome P450 Oxidoreductase in the Liver and Gastrointestinal Tract: A New Model for Studying the Functions of the P450 System , 2007, Journal of Pharmacology and Experimental Therapeutics.
[324] Lang Li,et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. , 2007, Pharmacogenomics.
[325] M. Eichelbaum,et al. Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4α: Evidence for Direct Regulation in the Intestine , 2007, Drug Metabolism and Disposition.
[326] H. Mukai,et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients , 2007, Pharmacogenetics and genomics.
[327] C David Stout,et al. Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.
[328] P. Carrupt,et al. Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers , 2007, Clinical pharmacology and therapeutics.
[329] W. Haefeli,et al. CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir , 2007, Clinical pharmacology and therapeutics.
[330] P. Nürnberg,et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. , 2007, Pharmacogenomics.
[331] M Schwab,et al. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.
[332] G. Kearns,et al. Ontogeny of Dextromethorphan O‐ and N‐demethylation in the First Year of Life , 2007, Clinical pharmacology and therapeutics.
[333] J. Goldstein,et al. Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular Tissues , 2007, Drug Metabolism and Disposition.
[334] M. Kodaira,et al. Pharmacogenomics‐based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori , 2007, Clinical pharmacology and therapeutics.
[335] H. McLeod,et al. A Novel Duplication Type of CYP2A6 Gene in African-American Population , 2007, Drug Metabolism and Disposition.
[336] M. Ingelman-Sundberg,et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans , 2007, European Journal of Clinical Pharmacology.
[337] M. Negishi,et al. CAR and PXR: The xenobiotic-sensing receptors , 2007, Steroids.
[338] V. Natarajan,et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda , 2007, HIV medicine.
[339] U. Fuhr,et al. Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach , 2007, Clinical pharmacology and therapeutics.
[340] E. Lobenhofer,et al. Hepatic Transcript Levels for Genes Coding for Enzymes Associated with Xenobiotic Metabolism are Altered with Age , 2007, Toxicologic pathology.
[341] E. Hodgson,et al. The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. , 2007, Pharmacology & therapeutics.
[342] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[343] Jiunn H Lin,et al. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. , 2007, Current drug metabolism.
[344] Yi-Tong Liu,et al. Drugs as CYP3A Probes, Inducers, and Inhibitors , 2007, Drug metabolism reviews.
[345] Hongbing Wang,et al. Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.
[346] F. Gonzalez. CYP2E1 , 2006, Drug Metabolism and Disposition.
[347] C. Adithan,et al. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. , 2007, Current clinical pharmacology.
[348] U. Klotz. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. , 2007, Clinical pharmacokinetics.
[349] R. Novak,et al. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. , 2007, Pharmacology & therapeutics.
[350] D. Seripa,et al. enetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug – Related astroduodenal Bleeding : Role of Cytochrome P 450 2 C 9 Polymorphisms , 2007 .
[351] U. Fuhr,et al. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping , 2007, European Journal of Clinical Pharmacology.
[352] K. Brøsen,et al. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. , 2006, British journal of clinical pharmacology.
[353] U. Fuhr,et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype , 2006, Clinical pharmacology and therapeutics.
[354] D. Nebert,et al. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.
[355] M. Nakajima,et al. Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α , 2006, Journal of Pharmacology and Experimental Therapeutics.
[356] D. Zeldin,et al. Variability of CYP2J2 Expression in Human Fetal Tissues , 2006, Journal of Pharmacology and Experimental Therapeutics.
[357] A. Bura,et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.
[358] N. Benowitz,et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior , 2006, Clinical pharmacology and therapeutics.
[359] M. Eichelbaum,et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.
[360] Shingo Takagi,et al. MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.
[361] H. McLeod,et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations , 2006, Clinical pharmacology and therapeutics.
[362] Gideon Koren,et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.
[363] T. Starzynska,et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.
[364] W. Miller,et al. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia , 2006, Current opinion in pediatrics.
[365] D. Roden,et al. Pharmacogenetics of antiarrhythmic therapy , 2006, Expert opinion on pharmacotherapy.
[366] Luke O Dannenberg,et al. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation , 2006, BMC Genomics.
[367] U. Klotz. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. , 2006, International journal of clinical pharmacology and therapeutics.
[368] Namandjé N. Bumpus,et al. Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms , 2006, Journal of Pharmacology and Experimental Therapeutics.
[369] P. A. Ladd,et al. Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. , 2006, Toxicology and applied pharmacology.
[370] Kaoru Kobayashi,et al. INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER , 2006, Drug Metabolism and Disposition.
[371] F. Gonzalez,et al. A Common Regulatory Region Functions Bidirectionally in Transcriptional Activation of the Human CYP1A1 and CYP1A2 Genes , 2006, Molecular Pharmacology.
[372] C. Smith,et al. Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.
[373] Christina N. Lessov-Schlaggar,et al. Female sex and oral contraceptive use accelerate nicotine metabolism , 2006, Clinical pharmacology and therapeutics.
[374] J. Stevens. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. , 2006, Drug discovery today.
[375] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[376] Li Jin,et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype , 2006, Pharmacogenetics and genomics.
[377] P. Neuvonen,et al. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine , 2006, European Journal of Clinical Pharmacology.
[378] R. Tyndale,et al. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine , 2006, Neuropharmacology.
[379] C. Jepson,et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy , 2006, Molecular Psychiatry.
[380] Bu Hz,et al. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. , 2006 .
[381] J. Brockmöller,et al. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. , 2006, Chemical research in toxicology.
[382] Makiko Maeda,et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation , 2006, The Pharmacogenomics Journal.
[383] B. Roe,et al. Sequence diversity and haplotype structure at the human CYP3A cluster , 2006, The Pharmacogenomics Journal.
[384] Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. , 2006, Canadian journal of physiology and pharmacology.
[385] E. Spina,et al. No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. , 2006, Pharmacological research.
[386] R. V. van Schaik,et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. , 2006, British journal of clinical pharmacology.
[387] K. Tashima,et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[388] T. A. Richardson,et al. Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.
[389] M. Shimizu,et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[390] Leif Bertilsson,et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.
[391] A. D. Rodrigues,et al. GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.
[392] Frank E. Blaney,et al. Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.
[393] H-Z Bu,et al. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. , 2006, Current drug metabolism.
[394] A. Daly. Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.
[395] M. Nakajima,et al. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. , 2006, The Journal of pharmacology and experimental therapeutics.
[396] E. Kimby,et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[397] A. Cederbaum. CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. , 2006, The Mount Sinai journal of medicine, New York.
[398] D. Nelson,et al. Cytochrome P450 nomenclature, 2004. , 2006, Methods in molecular biology.
[399] M. Hopkins,et al. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies , 2006, The Pharmacogenomics Journal.
[400] David A. Flockhart,et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.
[401] M. Ingelman-Sundberg,et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. , 2005, Biochemical and biophysical research communications.
[402] M. Eichelbaum,et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.
[403] C. Eap,et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.
[404] T. Fukami,et al. CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS , 2005, Drug Metabolism and Disposition.
[405] Sharon Marsh,et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel , 2005, Clinical Cancer Research.
[406] A. Gaedigk,et al. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? , 2005, Biochemical and biophysical research communications.
[407] M. Eichelbaum,et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study , 2005, Clinical pharmacology and therapeutics.
[408] M. Haberl,et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians , 2005, Pharmacogenetics and genomics.
[409] M. Ingelman-Sundberg,et al. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele , 2005, Pharmacogenetics and genomics.
[410] A. Gaedigk,et al. Variability of CYP3A7 Expression in Human Fetal Liver , 2005, Journal of Pharmacology and Experimental Therapeutics.
[411] E. Schuetz,et al. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. , 2005, Current drug metabolism.
[412] J. Brockmöller,et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. , 2005, British journal of clinical pharmacology.
[413] Michel Roger,et al. CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS , 2005, Drug Metabolism and Disposition.
[414] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[415] Namandjé N. Bumpus,et al. THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION , 2005, Drug Metabolism and Disposition.
[416] C. Martinez-Jimenez,et al. Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein β Isoforms (Liver Activating Protein and Liver Inhibitory Protein) , 2005, Molecular Pharmacology.
[417] Oliver Burk,et al. Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.
[418] M. Eichelbaum,et al. A Natural CYP2B6 TATA Box Polymorphism (–82T→ C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site , 2005, Molecular Pharmacology.
[419] U. Hofmann,et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. , 2005, Clinical pharmacology and therapeutics.
[420] Joseph Sack,et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. , 2005, American journal of human genetics.
[421] Václav Martínek,et al. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. , 2005, Cancer letters.
[422] I. Roots,et al. Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. , 2005, Cancer research.
[423] J. Ioannidis,et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis , 2005, Pharmacogenetics and genomics.
[424] D. Nebert,et al. Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC‐transgenic mice carrying the human CYP1A1_CYP1A2 locus , 2005, Human mutation.
[425] H. Glaeser,et al. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. , 2005, British journal of clinical pharmacology.
[426] S. Leucht,et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. , 2005, Clinical chemistry.
[427] J. Hakkola,et al. Regulation of CYP3A genes in the human respiratory tract. , 2005, Chemico-biological interactions.
[428] D. Greenblatt,et al. The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.
[429] J. Halpert,et al. Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.
[430] Jeffrey P. Jones,et al. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. , 2005, Annual review of pharmacology and toxicology.
[431] M Ingelman-Sundberg,et al. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.
[432] G. Koren,et al. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity , 2005, Pediatric Nephrology.
[433] Y. Daali,et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.
[434] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[435] K. Kosaki,et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam , 2004, Brain and Development.
[436] Felix W Frueh,et al. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. , 2004, Pharmacogenomics.
[437] Kyoichi Ohashi,et al. Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.
[438] A. Weston,et al. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. , 2004, American journal of epidemiology.
[439] K. Lindpaintner,et al. Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.
[440] U. Meyer,et al. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. , 2004, Pharmacogenetics.
[441] A. El-Sohemy,et al. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction , 2004, Journal of Medical Genetics.
[442] M. Eichelbaum,et al. Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles , 2004, Journal of Pharmacology and Experimental Therapeutics.
[443] J. Brockmöller,et al. The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)* , 2004, Journal of Biological Chemistry.
[444] Ulrich Klotz,et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori , 2004, Clinical pharmacology and therapeutics.
[445] Urs A. Meyer,et al. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.
[446] M. Eichelbaum,et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects , 2004, Clinical pharmacology and therapeutics.
[447] J. Agúndez,et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms , 2004, Clinical pharmacology and therapeutics.
[448] U. Klotz,et al. CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.
[449] Allan B. Okey,et al. Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* , 2004, Journal of Biological Chemistry.
[450] M. Ingelman-Sundberg,et al. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). , 2004, Pharmacogenetics.
[451] R. Obach,et al. Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[452] Martin Widschwendter,et al. Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.
[453] Jose A G Agundez,et al. Cytochrome P450 gene polymorphism and cancer. , 2004, Current drug metabolism.
[454] J. Villeneuve,et al. Cytochrome P450 and liver diseases. , 2004, Current drug metabolism.
[455] M. Kinirons,et al. Drug metabolism and ageing. , 2004, British journal of clinical pharmacology.
[456] J Licinio,et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.
[457] T. Skaar,et al. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.
[458] D. Greenblatt,et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.
[459] A. El-Kadi,et al. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. , 2004, Current drug metabolism.
[460] A. Rettie,et al. Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[461] P. Neuvonen,et al. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. , 2004, British journal of clinical pharmacology.
[462] Oliver Burk,et al. Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.
[463] Geraldine A Hamilton,et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[464] H. Yamazaki,et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. , 2004, Molecular pharmacology.
[465] F Peter Guengerich,et al. Functional characterization of four allelic variants of human cytochrome P450 1A2. , 2004, Archives of biochemistry and biophysics.
[466] E. Jabs,et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome , 2004, Nature Genetics.
[467] A. Cederbaum,et al. Oxidative stress, toxicology, and pharmacology of CYP2E1. , 2004, Annual review of pharmacology and toxicology.
[468] M. Eichelbaum,et al. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.
[469] L. Maltais,et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.
[470] R. Greenblatt,et al. Sex differences in pharmacokinetics and pharmacodynamics. , 2004, Annual review of pharmacology and toxicology.
[471] K. Brøsen. Some aspects of genetic polymorphism in the biotransformation of antidepressants. , 2004, Therapie.
[472] D. Lewis,et al. Substrates of Human Cytochromes P4S0 from Families CYP1 and CYP2: Analysis of Enzyme Selectivity and Metabolism , 2004, Drug metabolism and drug interactions.
[473] R. Preisig,et al. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man , 2004, European Journal of Clinical Pharmacology.
[474] T. Nurminen,et al. Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. , 2003, Cancer research.
[475] B. Ring,et al. Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.
[476] M. Eichelbaum,et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.
[477] Xinxin Ding,et al. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.
[478] R. Dhir,et al. Interpulse growth hormone secretion in the episodic plasma profile causes the sex reversal of cytochrome P450s in senescent male rats , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[479] N. Benowitz,et al. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism , 2003, Clinical pharmacology and therapeutics.
[480] P. Neuvonen,et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide , 2003, Clinical pharmacology and therapeutics.
[481] Peter Neuhaus,et al. Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.
[482] J. Sasse,et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.
[483] M. Fromm,et al. Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.
[484] C. Tickle,et al. Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis , 2003, Molecular and Cellular Biology.
[485] W. Weimar,et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.
[486] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[487] H. Cui,et al. Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene , 2003, Journal of Biological Chemistry.
[488] D. Mash,et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.
[489] J. Pascussi,et al. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. , 2003, Molecular pharmacology.
[490] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[491] M. Ingelman-Sundberg,et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[492] W. Backes,et al. Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. , 2003, Pharmacology & therapeutics.
[493] M. Ingelman-Sundberg,et al. Transcriptional Regulation of Human CYP3A4 Basal Expression by CCAAT Enhancer-Binding Protein α and Hepatocyte Nuclear Factor-3γ , 2003 .
[494] Hongbing Wang,et al. A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression* , 2003, The Journal of Biological Chemistry.
[495] S. Clarke,et al. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.
[496] Ricarda Thier,et al. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine , 2003, International archives of occupational and environmental health.
[497] L. S. Steijns,et al. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. , 2003, Pharmacogenetics.
[498] Ai-Ming Yu,et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.
[499] J. Idle,et al. The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.
[500] Wooin Lee,et al. The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.
[501] M. Ingelman-Sundberg,et al. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. , 2003, Molecular pharmacology.
[502] M. Kitada. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. , 2003, International journal of clinical pharmacology research.
[503] U. Yasar,et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.
[504] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[505] S. Bandiera,et al. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.
[506] P. Neuvonen,et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.
[507] G. Mannens,et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. , 2002, Biochemical pharmacology.
[508] J. Castell,et al. Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[509] Xiaoping Chen,et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. , 2002, British journal of clinical pharmacology.
[510] T. Matsubara,et al. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[511] D. Russell,et al. Clinical importance of the cytochromes P450 , 2002, The Lancet.
[512] J. Brockmöller,et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[513] S. Kliewer,et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.
[514] Sharon Miksys,et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.
[515] K. Kyvik,et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. , 2002, Pharmacogenetics.
[516] M. Eichelbaum,et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.
[517] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[518] H. Glaeser,et al. Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.
[519] E. Schuetz,et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.
[520] G. Giles,et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.
[521] P. Wilson,et al. Association Between the PPARA L162V Polymorphism and Plasma Lipid Levels: The Framingham Offspring Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[522] J. Goldstein,et al. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.
[523] H. Mohrenweiser,et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.
[524] M. Ingelman-Sundberg,et al. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. , 2002, Molecular pharmacology.
[525] C. Kasper,et al. Association of Multiple Developmental Defects and Embryonic Lethality with Loss of Microsomal NADPH-Cytochrome P450 Oxidoreductase* , 2002, The Journal of Biological Chemistry.
[526] Tommy B Andersson,et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. , 2002, The Journal of pharmacology and experimental therapeutics.
[527] M. Eichelbaum,et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. , 2002, Analytical Biochemistry.
[528] M. Ingelman-Sundberg,et al. The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity , 2002, Clinical pharmacology and therapeutics.
[529] C. Meisner,et al. Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. , 2002, Pharmacogenetics.
[530] A. Rosman,et al. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. , 2002, Journal of hepatology.
[531] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[532] T. Adachi,et al. Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. , 2002, Molecular pharmacology.
[533] M. Haberl,et al. The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.
[534] J. Idle,et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.
[535] J. Schenkman,et al. Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism. , 2001, Pharmacogenetics.
[536] D. Nelson,et al. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. , 2001, Pharmacogenetics.
[537] J. Goldstein,et al. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.
[538] J. Goldstein,et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.
[539] O Pelkonen,et al. Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.
[540] M Schwab,et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.
[541] U. Hofmann,et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.
[542] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[543] D. Yim,et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.
[544] M. Eichelbaum,et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.
[545] W. F. Greenlee,et al. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. , 2001, Annual review of pharmacology and toxicology.
[546] H. Yamazaki,et al. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[547] C. Lindley,et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[548] Jun-yan Hong,et al. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.
[549] A. Paterson,et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.
[550] J. Witte,et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.
[551] C. Wolf,et al. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. , 2000, Pharmacogenetics.
[552] K. Kreth,et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.
[553] O. Pelkonen,et al. CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.
[554] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[555] A. Gaedigk. Interethnic differences of drug-metabolizing enzymes. , 2000, International journal of clinical pharmacology and therapeutics.
[556] H. Zhou,et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. , 2000, British journal of clinical pharmacology.
[557] C. Hiemke,et al. Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.
[558] T. Kubota,et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele , 2000, European Journal of Clinical Pharmacology.
[559] H Derendorf,et al. Gender differences in pharmacokinetics and pharmacodynamics. , 1999, International journal of clinical pharmacology and therapeutics.
[560] K. Ley,et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.
[561] P. Beaune,et al. Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.
[562] J. Brockmöller,et al. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.
[563] T. Kamataki,et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.
[564] Paavo Honkakoski,et al. The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene* , 1999, The Journal of Biological Chemistry.
[565] J. Ward,et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[566] Kiyoshi Inoue,et al. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.
[567] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[568] P. Gøtzsche,et al. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. , 1998, Pharmacogenetics.
[569] D. G. McCarver,et al. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. , 1998, Toxicology and applied pharmacology.
[570] M. Eichelbaum,et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.
[571] M. Eichelbaum,et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.
[572] T. Cresteil. Onset of xenobiotic metabolism in children: toxicological implications. , 1998, Food additives and contaminants.
[573] T. Rebbeck,et al. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.
[574] S. Dehal,et al. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.
[575] J A McKay,et al. Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.
[576] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[577] C. Lieber,et al. Cytochrome P-4502E1: its physiological and pathological role. , 1997, Physiological reviews.
[578] J. Sheller,et al. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. , 1997, The Journal of pharmacology and experimental therapeutics.
[579] J. Brockmöller,et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.
[580] U. Meyer,et al. Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.
[581] C. Wolf,et al. Characterization of the Human Cytochrome P4502D6 Promoter , 1996, The Journal of Biological Chemistry.
[582] U. Hofmann,et al. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.
[583] T. Cresteil,et al. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.
[584] K. Tomer,et al. Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.
[585] H. Yamazaki,et al. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[586] R. Kim,et al. Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms , 1995, Clinical pharmacology and therapeutics.
[587] B. Lake,et al. Expression and alternative splicing of the cytochrome P-450 CYP2A7. , 1995, The Biochemical journal.
[588] G R Wilkinson,et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.
[589] D. Schrenk,et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.
[590] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[591] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[592] K. Brøsen,et al. Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.
[593] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[594] G. F. Weber,et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.
[595] S. Wrighton,et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.
[596] A. Rosman,et al. Induction of cytochrome P‐4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA , 1993, Hepatology.
[597] M. Ingelman-Sundberg,et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.
[598] M. Relling,et al. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.
[599] U. Meyer,et al. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.
[600] L. Bertilsson,et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype , 1990 .
[601] R. Skoda,et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.
[602] B. Dvorchik,et al. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[603] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[604] M. Eastwood,et al. NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.